Show simple item record

dc.contributor.authorAmiel, Stephanie A.
dc.contributor.authorAschner, Pablo
dc.contributor.authorChilds, Belinda P.
dc.contributor.authorCryer, Philip E.
dc.contributor.authorde Galan, Bastiaan
dc.contributor.authorHeller, Simon R.
dc.contributor.authorFrier, Brian M.
dc.contributor.authorGonder-Frederick, Linda
dc.contributor.authorJones, Timothy
dc.contributor.authorKhunti, Kamlesh
dc.contributor.authorLeiter, Lawrence A.
dc.contributor.authorLuo, Yingying
dc.contributor.authorVigersky, Robert
dc.contributor.authorZoungas, Sophia
dc.date.accessioned2015-08-20T19:35:14Z
dc.date.available2015-08-20T19:35:14Z
dc.date.issued2015-08
dc.identifier.citationAmiel, Stephanie A.; Aschner, Pablo; Childs, Belinda P.; Cryer, Philip E.; de Galan, Bastiaan; Heller, Simon R.; Frier, Brian M.; Gonder-Frederick, Linda; Jones, Timothy; Khunti, Kamlesh; Leiter, Lawrence A.; Luo, Yingying; Vigersky, Robert; Zoungas, Sophia. 2015. Minimizing hypoglycemia in diabetes. Diabetes Care, August 2015:vol. 38:no. 8:pp 1583-1591en_US
dc.identifier.issn0149-5992
dc.identifier.otherWOS:000358673200036
dc.identifier.urihttp://dx.doi.org/10.2337/dc15-0279
dc.identifier.urihttp://hdl.handle.net/10057/11475
dc.descriptionClick on the DOI link to access the article (may not be free).en_US
dc.description.abstractHypoglycemia caused by treatment with a sulfonylurea, a glinide, or insulin coupled with compromised defenses against the resulting falling plasma glucose concentrations is a problem for many people with diabetes. It is often recurrent, causes significant morbidity and occasional mortality, limits maintenance of euglycemia, and impairs physiological and behavioral defenses against subsequent hypoglycemia. Minimizing hypoglycemia includes acknowledging the problem; considering each risk factor; and applying the principles of intensive glycemic therapy, including drug selection and selective application of diabetes treatment technologies. For diabetes health-care providers treating most people with diabetes who are at risk for or are suffering from iatrogenic hypoglycemia, these principles include selecting appropriate individualized glycemic goals and providing structured patient education to reduce the incidence of hypoglycemia. This is typically combined with short-term scrupulous avoidance of hypoglycemia, which often will reverse impaired awareness of hypoglycemia. Clearly, the risk of hypoglycemia is modifiable.en_US
dc.description.sponsorshipThe International Hypoglycaemia Study Group (IHSG) is supported through an unrestricted educational grant from Novo Nordisk awarded to Six Degrees Academy (SDA) of Toronto, Ontario, Canada. Along with the IHSG chair, SDA has been solely responsible for membership recruitment/selection and content/outcomes for the meetings. The rationale for the formation of IHSG is that hypoglycemia is an underrecognized problem that deserves increased awareness and focus across the healthcare community. The group's ultimate goal is to improve the lives of patients with diabetes. P.A. has served on scientific advisory boards and/or as a lecturer for AstraZeneca, Boehringer Ingelheim/Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Novartis, and Sanofi. B.C. had research grant support from Halozyme and Lilly to the former MidAmerica Diabetes Associates. P.E.C. has served on scientific advisory boards for Boehringer Ingelheim/Lilly, Calibrium, Merck Sharp & Dohme, Novo Nordisk, and Pfizer. B.d.G. has served on scientific advisory boards for Merck Sharp & Dohme, Novo Nordisk, and Sanofi and received research grant support from Europharma Group. S.R.H. has served on scientific advisory boards and provided consultations for which his institution has received remuneration from Lilly, Novo Nordisk, Takeda, Merck Sharp & Dohme, and Becton Dickinson and has served as a speaker for which he received remuneration from Lilly, Novo Nordisk, Boehringer Ingelheim, and Takeda. B.M.F. has served on scientific advisory boards and as a speaker for Boehringer Ingelheim, Janssen, Lilly, Merck Sharp & Dohme, Novo Nordisk, and Lilly. L.G.-F. has served as a consultant or speaker and/or has received research grant support from Abbott Diabetes Care, AstraZeneca, Dexcom, Johnson & Johnson, and Merck Sharp & Dohme. T.J. has served as a speaker for Novo Nordisk, Lilly, Medtronic, and Sanofi. K.K. has served as a consultant or speaker for AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi and has received research grant support from AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, Roche, and Sanofi. L.A.L. has served as a consultant or speaker for Abbott, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Novo Nordisk, Sanofi, Servier, and Takeda. R.V. has served as a consultant for Medtronic and has received research grant support from Dexcom. S.Z. has served on scientific advisory boards for Amgen, Bristol-Myers Squibb, AstraZeneca, Janssen, Merck Sharp & Dohme, Novo Nordisk, Sanofi, and Takeda; has served as a speaker for Bristol-Myers Squibb, AstraZeneca, Janssen, Merck Sharp & Dohme, Servier, and Takeda; and has received research grant support from Bristol-Myers Squibb and AstraZeneca.en_US
dc.language.isoen_USen_US
dc.publisherAmerican Diabetes Associationen_US
dc.relation.ispartofseriesDiabetes Care;v.38:no.8
dc.subjectSubcutaneous insulin infusionen_US
dc.subjectMultiple daily injectionsen_US
dc.subjectRandomized controlled-trialsen_US
dc.subjectAll-cause mortalityen_US
dc.subjectGlycemic controlen_US
dc.subjectGlucose controlen_US
dc.subjectCardiovascular-diseaseen_US
dc.subjectStructured educationen_US
dc.subjectCardiac-arrhythmiasen_US
dc.subjectImpaired awarenessen_US
dc.titleMinimizing hypoglycemia in diabetesen_US
dc.typeArticleen_US
dc.rights.holder© 2015 by the American Diabetes Association.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record